CROs Highlight Toxicology Revenue; Are Mergers Non-Toxic To Bottom Line?
Covance expects its expanding toxicology research to drive double-digit revenue growth through 2003
You may also be interested in...
Pfizer's $11 bil. premium above Pharmacia's recent stock market valuation is a figure calculated from the estimated operating savings in the companies' proposed stock-for-stock transaction
Corcept Therapeutics will test the sluggish market for biopharmaceutical initial public offerings with an IPO slated for June 10
Covance will use cash generated from the divestment of its biomanufacturing business to fund capacity expansion for its Madison, Wisc., toxicology facility, CEO Chris Kuebler told analysts.